Rubedo Life is a company that focuses on leveraging machine learning and AI in drug discovery and molecular property prediction, with a strong emphasis on advancing human intelligence in the field of healthcare and pharmaceuticals.

Mark Gallop

Julian Klein

Marco Quarta

Rubedo Life

Rubedo Life Sciences is a biopharmaceutical company developing a broad portfolio of innovative therapies engineered to target cells which drive chronic age-related diseases. Our proprietary ALEMBIC™ drug discovery platform has engineered novel first-in-class small molecules designed to selectively target senescent cells, which play a key role in the progression of pulmonary, dermatological, oncological, neurodegenerative, fibrotic and other chronic disorders. The Rubedo leadership team is composed of industry leaders and pioneers in chemistry, technology, and the life sciences, with a deep bench of expertise in drug development and commercialization spanning from large pharma to biotech innovators. The company is based in Sunnyvale, CA.

California Institute for Regenerative Medicine

Khosla Ventures

Refactor Capital

The Longevity Fund

Shanda Group

Rubedo Life Sciences

Rubedo CEO Dr. Marco Quarta will be speaking at Longwood Healthcare Leaders panel on "Advancing Research into the Clinic" along with other leaders in the field, A. Stewart Campbell from Axial, Susan Hill from Mestag Therapeutics, Sunil Verma from AstraZeneca and Robert LaCaze from Mnemo Therapeutics. Reach out and meet us there, ahead of JPM Healthcare Conference week. 


Our CEO, Dr. Marco Quarta will be speaking at #BiotechShowcase during the J.P. Morgan HealthCare Conference Week, giving an update on our therapeutic pipeline and development. Come and join us, with CBO Ali Siam, to hear the exciting news on Monday January 8th at 10:00 am in Franciscan B (Ballroom Level). 

On January 9th, Dr. Quarta will be speaking on the panel dedicated to the  #ScienceOfLongevity along with other leading experts and founders of #LongevityMedicines companies Hanadie Yousef of Juvena Therapeutics; John Ramunas of Rejuvenation Technologies Inc. and Mark Kotter of @Clock.bio with the panel led by the fantastic Ed Saltzman of Lumanity. 

We hope to see you there!

Metric
Company Name	Rubedo Life
Symbol
MSH ID	COM:RUBEDOLIFE
Market	PRIVATE
Sector	Healthcare & Health Services
Industry	Healthcare & Health Services
Country	US
Stage
Employee Count	25
Website	rubedolife.com
LinkedIn	rubedo-life-sciences
Founders

Metric
Market Cap
Enterprise Value
Monthly Web Traffic
Web Traffic Growth
Valuation
Raised Capital

Metric
Revenue
Revenue (LTM)
Revenue (NTM)
Gross Profit
EBITDA
Operating Income
Net Income
EPS
Diluted EPS
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin
Operating Profit Margin
EBITDA Margin
Net Profit Margin
Return on Equity
Return on Assets
Return on Capital Employed

COM:RUBEDOLIFE

Rubedo Life

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio
P/B Ratio
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio
EV Multiple

Metric
Days Sales Outstanding
Days Payables Outstanding
Days Inventory Outstanding
Operating Cycle
Cash Conversion Cycle
Asset Turnover

Metric
Operating Cash Flow
Free Cash Flow
Cash Flow to Debt
Operating Cash Flow/Sales
Free Cash Flow Yield

Metric
Cash & Equivalents
Accounts Receivable
Inventory
Goodwill
Debt to Capitalization
Debt to Assets
Current Ratio
Quick Ratio

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue
R&D to Revenue
SG&A to Revenue